Literature DB >> 7049306

Control of malignant ascites with spironolactone.

B Greenway, P J Johnson, R Williams.   

Abstract

Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment. Plasma renin activity was raised in all of 5 patients in whom it was measured, whereas aldosterone was raised in only 3; these results are similar to those found in ascites due to cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049306     DOI: 10.1002/bjs.1800690802

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

3.  Symptom management in hepatocellular carcinoma.

Authors:  Virginia Chih-Yi Sun; Linda Sarna
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

4.  Measuring symptoms in terminal cancer: are pain and dyspnoea controlled?

Authors:  I Higginson; M McCarthy
Journal:  J R Soc Med       Date:  1989-05       Impact factor: 18.000

5.  Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.

Authors:  Tomomi Sanomachi; Shuhei Suzuki; Keita Togashi; Asuka Sugai; Shizuka Seino; Masashi Okada; Takashi Yoshioka; Chifumi Kitanaka; Masahiro Yamamoto
Journal:  Cancers (Basel)       Date:  2019-10-14       Impact factor: 6.639

Review 6.  Management of ascites due to gastrointestinal malignancy.

Authors:  Muhammad W Saif; Imran A P Siddiqui; Muhammad A Sohail
Journal:  Ann Saudi Med       Date:  2009 Sep-Oct       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.